Immix Biopharma (IMMX) Short Interest Ratio & Short Volume $1.87 +0.12 (+6.86%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.84 -0.03 (-1.60%) As of 04/25/2025 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Immix Biopharma Short Interest DataImmix Biopharma (IMMX) has a short interest of 346,800 shares, representing 2.10% of the float (the number of shares available for trading by the public). This marks a -5.61% decrease in short interest from the previous month. The short interest ratio (days to cover) is 5.2, indicating that it would take 5.2 days of the average trading volume of 125,143 shares to cover all short positions.Current Short Interest346,800 sharesPrevious Short Interest367,400 sharesChange Vs. Previous Month-5.61%Dollar Volume Sold Short$582,624.00Short Interest Ratio5.2 Days to CoverLast Record DateMarch 31, 2025Outstanding Shares27,722,000 sharesFloat Size16,510,000 sharesShort Percent of Float2.10%Today's Trading Volume68,224 sharesAverage Trading Volume125,143 sharesToday's Volume Vs. Average55% Short Selling Immix Biopharma? Sign up to receive the latest short interest report for Immix Biopharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartIMMX Short Interest Over TimeIMMX Days to Cover Over TimeIMMX Percentage of Float Shorted Over Time Immix Biopharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/2025346,800 shares $582,624.00 -5.6%2.1%5.2 $1.68 3/15/2025367,400 shares $606,210.00 -4.9%2.2%4.1 $1.65 2/28/2025386,300 shares $687,614.00 -0.8%2.4%3.3 $1.78 2/15/2025389,400 shares $771,012.00 +16.1%2.4%2.4 $1.98 1/31/2025335,300 shares $650,482.00 -11.5%2.1%2.1 $1.94 1/15/2025378,900 shares $765,378.00 +6.3%2.3%2.4 $2.02 12/31/2024356,500 shares $784,300.00 -11.0%2.2%2.2 $2.20 12/15/2024400,500 shares $817,020.00 -14.9%2.4%2.3 $2.04 11/30/2024470,700 shares $993,177.00 +17.5%2.9%3 $2.11 11/15/2024400,700 shares $637,113.00 -7.9%2.5%3.2 $1.59 Get the Latest News and Ratings for IMMX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter. 10/31/2024434,900 shares $695,840.00 -3.5%2.7%3.9 $1.60 10/15/2024450,500 shares $662,235.00 -18.5%2.8%3.2 $1.47 9/30/2024552,800 shares $823,672.00 +15.2%3.4%3.8 $1.49 9/15/2024479,700 shares $892,242.00 +48.1%2.9%3.2 $1.86 8/31/2024324,000 shares $693,360.00 -43.0%2.0%2.1 $2.14 8/15/2024568,400 shares $1.07 million -1.7%3.6%3.6 $1.89 7/31/2024578,200 shares $1.20 million -7.5%3.8%3.6 $2.07 7/15/2024625,300 shares $1.28 million +12.2%4.1%4.5 $2.04 6/30/2024557,400 shares $1.10 million +17.8%3.6%3.8 $1.98 6/15/2024473,100 shares $974,586.00 +39.7%3.1%3.6 $2.06 5/31/2024338,700 shares $714,657.00 -7.6%2.2%2.5 $2.11 5/15/2024366,500 shares $861,275.00 -5.4%2.4%2.3 $2.35 4/30/2024387,500 shares $840,875.00 +10.8%2.8%1.9 $2.17 4/15/2024349,900 shares $930,734.00 -10.0%2.5%1.3 $2.66 3/31/2024388,800 shares $1.19 million +22.8%2.8%1.4 $3.07 3/15/2024316,600 shares $835,824.00 +19.9%3.1%1.1 $2.64 2/29/2024264,100 shares $884,735.00 -14.5%3.5%0.7 $3.35 2/15/2024308,900 shares $898,899.00 -37.0%4.1%0.9 $2.91 1/31/2024489,900 shares $1.87 million +123.2%6.4%1.4 $3.82 1/15/2024219,500 shares $1.28 million +3.1%2.9%0.8 $5.81 12/31/2023212,900 shares $1.47 million +52.3%2.8%0.8 $6.92 12/15/2023139,800 shares $1.02 million +0.1%1.8%0.5 $7.27 11/30/2023139,700 shares $713,867.00 -42.4%1.9%0.6 $5.11 11/15/2023242,600 shares $1.08 million -17.8%3.2%1.1 $4.46 10/31/2023295,000 shares $1.07 million +71.3%3.9%1.4 $3.62 10/15/2023172,200 shares $514,017.00 +71.7%2.3%0.9 $2.99 9/30/2023100,300 shares $343,026.00 +39.5%2.0%0.5 $3.42 9/15/202371,900 shares $191,973.00 -33.4%1.7%0.5 $2.67 8/31/2023107,900 shares $219,037.00 +65.0%2.5%0.8 $2.03 8/15/202365,400 shares $121,644.00 +10.3%0.9%0.4 $1.86The Trump Dump is starting; Get out of stocks now? (Ad)The first 365 days of the Trump presidency… Will be the best time to get rich in American history.If I’m right about this (like I was before) a modest $900 investment could grow to a life-changing a 7/31/202359,300 shares $122,158.00 +8.2%1.0%0.2 $2.06 7/15/202354,800 shares $125,492.00 -45.0%0.9%0.2 $2.29 6/30/202399,600 shares $267,924.00 -46.1%1.7%0.3 $2.69 6/15/2023184,700 shares $435,892.00 -16.2%3.1%0.6 $2.36 5/31/2023220,300 shares $445,006.00 +43.8%4.2%0.7 $2.02 5/15/2023153,200 shares $315,592.00 -30.8%2.9%0.5 $2.06 4/30/2023221,300 shares $546,611.00 +86.8%4.0%1.1 $2.47 4/15/2023118,500 shares $213,501.45 -23.1%2.1%1.2 $1.80 3/31/2023154,100 shares $280,462.00 +5.2%2.8%1.4 $1.82 3/15/2023146,500 shares $276,885.00 +24.3%2.5%0.8 $1.89 2/28/2023117,900 shares $245,232.00 +20.7%2.0%0.1 $2.08 2/15/202397,700 shares $225,687.00 -43.0%1.7%0.1 $2.31 1/31/2023171,400 shares $445,640.00 -0.9%2.9%0.1 $2.60 1/15/2023172,900 shares $380,380.00 -19.2%2.9%0.2 $2.20 12/30/2022214,100 shares $490,289.00 +128.3%3.6%0.2 $2.29 12/15/202293,800 shares $184,786.00 +281.3%1.6%0.1 $1.97 11/30/202224,600 shares $29,766.00 +5.1%0.4%0.5 $1.21 11/15/202223,400 shares $24,804.00 -20.1%0.4%0.4 $1.06 10/31/202229,300 shares $29,300.00 +8.1%0.5%0.6 $1.00 10/15/202227,100 shares $32,791.00 +11.1%0.5%0.7 $1.21 9/30/202224,400 shares $33,184.00 -60.5%0.4%0.5 $1.36 9/15/202261,700 shares $106,741.00 +92.8%1.1%0.6 $1.73 8/31/202232,000 shares $58,240.00 +111.9%0.6%0.2 $1.82 8/15/202215,100 shares $35,334.00 -74.5%0.3%0 $2.34 7/31/202259,300 shares $144,692.00 -46.5%1.0%0 $2.44 7/15/2022110,900 shares $302,757.00 No Change1.9%0 $2.73 IMMX Short Interest - Frequently Asked Questions What is Immix Biopharma's current short interest? Short interest is the volume of Immix Biopharma shares that have been sold short but have not yet been covered or closed out. As of March 31st, investors have sold 346,800 shares of IMMX short. 2.10% of Immix Biopharma's shares are currently sold short. Learn More on Immix Biopharma's current short interest. What is a good short interest ratio for Immix Biopharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IMMX shares currently have a short interest ratio of 5.0. Learn More on Immix Biopharma's short interest ratio. Which institutional investors are shorting Immix Biopharma? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Immix Biopharma: Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Immix Biopharma? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.10% of Immix Biopharma's floating shares are currently sold short. Is Immix Biopharma's short interest increasing or decreasing? Immix Biopharma saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 346,800 shares, a decline of 5.6% from the previous total of 367,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Immix Biopharma's float size? Immix Biopharma currently has issued a total of 27,722,000 shares. Some of Immix Biopharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Immix Biopharma currently has a public float of 16,510,000 shares. How does Immix Biopharma's short interest compare to its competitors? 2.10% of Immix Biopharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Immix Biopharma: Eledon Pharmaceuticals, Inc. (2.77%), Cardiff Oncology, Inc. (31.41%), MediWound Ltd. (13.40%), Tevogen Bio Holdings Inc. (4.88%), Voyager Therapeutics, Inc. (5.62%), Genfit S.A. (0.10%), Inventiva S.A. (0.95%), INmune Bio, Inc. (42.18%), Inhibrx, Inc. (9.30%), Annexon, Inc. (8.85%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.93 billion), iShares 20+ Year Treasury Bond ETF ($9.31 billion), Strategy Incorporated ($8.42 billion), Charter Communications, Inc. ($4.52 billion), Apollo Global Management, Inc. ($4.26 billion), Super Micro Computer, Inc. ($3.98 billion), Capital One Financial Co. ($3.79 billion), TC Energy Co. ($3.43 billion), AppLovin Co. ($2.91 billion), and Schlumberger Limited ($2.89 billion). View all of the most shorted stocks. What does it mean to sell short Immix Biopharma stock? Short selling IMMX is an investing strategy that aims to generate trading profit from Immix Biopharma as its price is falling. IMMX shares are trading up $0.12 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Immix Biopharma? A short squeeze for Immix Biopharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of IMMX, which in turn drives the price of the stock up even further. How often is Immix Biopharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IMMX, twice per month. The most recent reporting period available is March, 31 2025. More Short Interest Resources from MarketBeat Related Companies ELDN Short Interest CRDF Short Interest MDWD Short Interest TVGN Short Interest VYGR Short Interest GNFT Short Interest IVA Short Interest INMB Short Interest INBX Short Interest ANNX Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:IMMX) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot...Stansberry Research | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.